v3.26.1
SCHEDULE OF INFORMATION RELATED TO OPERATIONS OF REPORTABLE OPERATING SEGMENTS (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting [Line Items]    
Share base compensation $ 90 [1]
Change in fair value of contingent consideration (50) 103
Goodwill impairment (6,291)
Total Operating loss (8,225) (503)
Other income 386
Net loss before tax (7,447) (1,116)
Income taxes (23)
Net loss (6,589) (1,257)
Operating Segments [Member]    
Segment Reporting [Line Items]    
Professional services (423) (238)
Share base compensation (1,149) (41)
Change in fair value of contingent consideration 343
Goodwill impairment (6,291)
Depreciation (3)
Other general and administrative expenses (217) (153)
Total Operating loss (8,225) (503)
Interest of loans (77)
Financing expenses, net (100) (639)
Other income 386
Changes in fair value of investments measured under the fair value option 492 103
Net loss before tax (7,447) (1,116)
Income taxes 23
Net loss (7,424) (1,116)
Operating Segments [Member] | Biotechnology Activity [Member]    
Segment Reporting [Line Items]    
Revenue from renewable energy projects
Cost related to renewable energy projects [2] (125)
Salaries and related expenses related to biotechnology activity (256)
Amortization of intangible asset (100)
Operating loss from renewable energy projects (481)
Operating Segments [Member] | Renewable Energy Projects [Member]    
Segment Reporting [Line Items]    
Revenue from renewable energy projects
Cost related to renewable energy projects (4) (71)
Operating loss from renewable energy projects $ (4) $ (71)
[1] Less than $1 thousand.
[2] Costs related to biotechnology activity primarily consist of subcontractors engaged in research and development activities.